Shares of Evolent Health (EVH) plummeted 5.06% during Wednesday's intraday trading session, reflecting investor concern over the company's near-term prospects. The significant drop came as the healthcare company faced a notable revision in analyst expectations.

The catalyst for the sell-off appears to be Oppenheimer's decision to lower its price target on Evolent Health to $12 from $18, a substantial 33% reduction. Despite maintaining an Outperform rating on the stock, the dramatic cut in the price target suggests the firm has tempered its outlook for Evolent Health's future performance. This adjustment follows the company's recent quarterly results, indicating potential challenges in meeting previous growth expectations. While the full details of Oppenheimer's analysis were not provided, such a significant reduction in price target often prompts investors to reassess their positions, leading to increased selling pressure.